Skip to main content
Premium Trial:

Request an Annual Quote

XDx Drops IPO Plans

NEW YORK (GenomeWeb News) – Molecular diagnostics firm XDx has informed the US Securities and Exchange Commission that it is withdrawing its registration statement for an initial public offering.
 
The Brisbane, Calif.-based firm filed for the IPO in October 2007. At the time, the company did not say how many shares it would offer or how much money it expected to raise in the offering. It had expected to use the funds generated by the offering to expand infrastructure, propel R&D to support current and future tests, increase sales, marketing, and research staff, and expand facilities, as well as potential acquisitions.
 
XDx cited “current public market conditions” as the reason for its decision to withdraw the IPO.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.